
|Videos|February 22, 2018
Ongoing Studies for Patients with Relapsed/Refractory AML
Author(s)Daniel J. DeAngelo, MD, PhD
Advertisement
Daniel J. DeAngelo, MD, PhD, associate professor of medicine at Harvard Medical School, and a member of the Adult Leukemia Program at the Dana-Farber Cancer Institute, discusses some of the clinical trials currently ongoing for patients with relapsed/refractory acute myeloid leukemia (AML). DeAngelo says he primarily uses targeted and combination therapies.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
5


































